Scisparc Ltd (SPRC)

SciSparc announced that its subsidiary, NeuroThera Labs Inc., has advanced its collaboration with Clearmind Medicine Inc. with the U.S. publication of a patent application for a novel combination of MDMA and N-acylethanolamines for treating PTSD, anxiety, and eating disorders. This development aligns with increasing federal support for psychedelic medicine, including recent FDA guidance on MDMA. The collaboration has resulted in thirteen published patent applications globally, integrating NeuroThera’s PEA technology into Clearmind’s therapeutic programs.

SciSparc Ltd. (SPRC) announced the U.S. publication of a patent application for a novel combination of MDMA and N-acylethanolamines (including PEA) for treating PTSD, anxiety, and eating disorders, a result of its collaboration with Clearmind Medicine Inc. This adds to their joint intellectual property portfolio, which now totals thirteen published patent applications globally. The announcement coincides with the FDA's recent final guidance on psychedelic drug development, explicitly including MDMA, which provides regulatory context for SciSparc's MDMA-PEA program.

SciSparc Ltd.'s subsidiary NeuroThera Labs Inc. has published a U.S. patent application for a combination of MDMA and N-acylethanolamines to treat conditions like PTSD, anxiety, and eating disorders. This development follows new FDA guidance on psychedelic drugs for medical conditions, which explicitly includes MDMA. NeuroThera is a clinical-stage pharmaceutical company focused on CNS disorders, including drug development programs based on THC and CBD.

SciSparc's subsidiary NeuroThera Labs and collaborator Clearmind Medicine have advanced their partnership with the U.S. publication of a patent application for a novel combination of MDMA and N-acylethanolamines, targeting PTSD, anxiety, and eating disorders. This development aligns with the U.S. FDA's recent guidance explicitly including MDMA in psychedelic drug development, providing crucial regulatory context for their MDMA-PEA program. The collaboration now boasts 13 published patent applications globally, strengthening their intellectual property portfolio.

SciSparc's subsidiary, NeuroThera Labs, and Clearmind Medicine Inc. have advanced their collaboration with the U.S. publication of a patent application for a novel combination of MDMA and N-acylethanolamines (like PEA) to treat PTSD, anxiety, and eating disorders. This development comes as the FDA has finalized guidance on psychedelic drug development, explicitly including MDMA, providing a regulatory framework for their joint intellectual property. The collaboration integrates NeuroThera's PEA technology into Clearmind’s psychedelic programs, aiming to enhance therapeutic potency and address side effects.